Newsfeeds - Spark Newswire

1 minute read

Cantor Fitzgerald Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $14

Today, 3:54 PM

Cantor Fitzgerald analyst Emma Nealon initiates coverage on Equillium (NASDAQ:EQ) with a Overweight rating and announces Price Target of $14.

5 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:54 PM

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.

ABVC

1 minute read

Equillium’s Itolizumab Reduces Urine Protein In Lupus Patients

By Vandana Singh

Today, 3:54 PM

Equillium Inc (NASDAQ:EQ) announced additional data from the Type A portion of the EQUALISE Phase 1b study of itolizumab in systemic…

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 3:54 PM

Gainers

ACHV

1 minute read

Equillium Q2 EPS $(0.31) Up From $(0.37) YoY

By Benzinga Newsdesk

Today, 3:54 PM

Equillium (NASDAQ:EQ) reported quarterly losses of $(0.31) per share. This is a 16.22 percent increase over losses of $(0.37) per share from the same period last year.

5 minute read

64 Biggest Movers From Friday

By Lisa Levin

Today, 3:54 PM

Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share.

AEHL

2 minute read

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

Today, 3:54 PM

APTX

1 minute read

Equillium’s Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients

By Vandana Singh

Today, 3:54 PM

Equillium Inc (NASDAQ:EQ) has announced positive topline data from the Phase 1b EQUATE study evaluating itolizumab in first-line acute graft-versus-host-disease (aGVHD).…

4 minute read

FDA
News

Equillium Reports Topline Results From EQUATE Study In First-Line Treatment Of Acute Graft-Versus-Host Disease

By Benzinga Newsdesk

Today, 3:54 PM

Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in corticosteroid use Data support clinical advancement of itolizumab in

4 minute read

Uncategorized

46 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:54 PM

Gainers

AGFY